Special Survey for Paediatric Subjects

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin aspart

Study type: Observational

Funder types: Industry

Identifiers

NCT01487382

ANA-1945

Details and patient eligibility

About

This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using NovoRapid® (insulin aspart) in children with type 1 and type 2 diabetes under normal clinical practice conditions.

Enrollment: 241 patients

Sex: All

Ages: Under 15 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Requiring insulin therapy
• No treatment history of NovoRapid® (insulin aspart)

Trial design

241 participants in 1 patient group

Insulin Aspart

Treatment:

Drug: insulin aspart